OncoImmune Announces Completion of Phase II Trial

Published: 11/01/2019
OncoImmune Announces Completion of Phase II Trial
Source: WWW.BUSINESSWIRE.COM

ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that is has completed its Phase IIa trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT. The Phase IIa trial is a multicenter prospective randomized study designed to determine the MTD (Maximum Tolerated Dose) of CD24Fc for acute GVHD (Graft Versus Host Disease) prophylaxis. The last patient comp

Read more
Related news
Comment
FACEBOOK